

Global Prostate Cancer PARP Inhibitor Drugs Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/G0FA94D324A7EN.html>

Date: May 2023

Pages: 98

Price: US\$ 4,480.00 (Single User License)

ID: G0FA94D324A7EN

Abstracts

The global Prostate Cancer PARP Inhibitor Drugs market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Poly ADP-ribose polymerase (PARP) is a DNA repair enzyme involved in the single-strand repair process of DNA. PARP inhibitors (PARPi) inhibit PARP activity through two mechanisms: direct inhibition of PARP function and PARP trapping, resulting in the stalling and collapse of replication forks, resulting in fatal double-strand breaks. Normal cells can repair double-strand breaks in time and correctly through homologous recombination repair (HRR); however, in tumor cells carrying HRR gene mutations, due to the impairment or loss of HRR function, the accumulated double-strand breaks will not be repaired in time and correctly, resulting in The tumor cell genome is unstable and eventually induces tumor cell death.

This report studies the global Prostate Cancer PARP Inhibitor Drugs production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Prostate Cancer PARP Inhibitor Drugs, and provides market size (US\$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Prostate Cancer PARP Inhibitor Drugs that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Prostate Cancer PARP Inhibitor Drugs total production and demand, 2018-2029,

(K Units)

Global Prostate Cancer PARP Inhibitor Drugs total production value, 2018-2029, (USD Million)

Global Prostate Cancer PARP Inhibitor Drugs production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Prostate Cancer PARP Inhibitor Drugs consumption by region & country, CAGR, 2018-2029 & (K Units)

U.S. VS China: Prostate Cancer PARP Inhibitor Drugs domestic production, consumption, key domestic manufacturers and share

Global Prostate Cancer PARP Inhibitor Drugs production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)

Global Prostate Cancer PARP Inhibitor Drugs production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Prostate Cancer PARP Inhibitor Drugs production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)

This reports profiles key players in the global Prostate Cancer PARP Inhibitor Drugs market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Merck & Co., Inc, GSK, Pfizer, Johnson & Johnson, Takeda Pharmaceutical Company Limited, BeiGene, Inc and Jiangsu Hengrui Pharmaceuticals Co., Ltd, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Prostate Cancer PARP Inhibitor Drugs market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$

Millions), volume (production, consumption) & (K Units) and average price (US\$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Prostate Cancer PARP Inhibitor Drugs Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Prostate Cancer PARP Inhibitor Drugs Market, Segmentation by Type

Lynparza

Zejula

Talzenna

Fluzoparib

PamiPali

Other

Global Prostate Cancer PARP Inhibitor Drugs Market, Segmentation by Application

Hospital

Specialty Clinic

other

Companies Profiled:

AstraZeneca

Merck & Co., Inc

GSK

Pfizer

Johnson & Johnson

Takeda Pharmaceutical Company Limited

BeiGene, Inc

Jiangsu Hengrui Pharmaceuticals Co., Ltd

Key Questions Answered

1. How big is the global Prostate Cancer PARP Inhibitor Drugs market?
2. What is the demand of the global Prostate Cancer PARP Inhibitor Drugs market?
3. What is the year over year growth of the global Prostate Cancer PARP Inhibitor Drugs market?
4. What is the production and production value of the global Prostate Cancer PARP Inhibitor Drugs market?

5. Who are the key producers in the global Prostate Cancer PARP Inhibitor Drugs market?

6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Prostate Cancer PARP Inhibitor Drugs Introduction
- 1.2 World Prostate Cancer PARP Inhibitor Drugs Supply & Forecast
 - 1.2.1 World Prostate Cancer PARP Inhibitor Drugs Production Value (2018 & 2022 & 2029)
 - 1.2.2 World Prostate Cancer PARP Inhibitor Drugs Production (2018-2029)
 - 1.2.3 World Prostate Cancer PARP Inhibitor Drugs Pricing Trends (2018-2029)
- 1.3 World Prostate Cancer PARP Inhibitor Drugs Production by Region (Based on Production Site)
 - 1.3.1 World Prostate Cancer PARP Inhibitor Drugs Production Value by Region (2018-2029)
 - 1.3.2 World Prostate Cancer PARP Inhibitor Drugs Production by Region (2018-2029)
 - 1.3.3 World Prostate Cancer PARP Inhibitor Drugs Average Price by Region (2018-2029)
 - 1.3.4 North America Prostate Cancer PARP Inhibitor Drugs Production (2018-2029)
 - 1.3.5 Europe Prostate Cancer PARP Inhibitor Drugs Production (2018-2029)
 - 1.3.6 China Prostate Cancer PARP Inhibitor Drugs Production (2018-2029)
 - 1.3.7 Japan Prostate Cancer PARP Inhibitor Drugs Production (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Prostate Cancer PARP Inhibitor Drugs Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Prostate Cancer PARP Inhibitor Drugs Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
 - 1.5.1 Influence of COVID-19
 - 1.5.2 Influence of Russia-Ukraine War

2 DEMAND SUMMARY

- 2.1 World Prostate Cancer PARP Inhibitor Drugs Demand (2018-2029)
- 2.2 World Prostate Cancer PARP Inhibitor Drugs Consumption by Region
 - 2.2.1 World Prostate Cancer PARP Inhibitor Drugs Consumption by Region (2018-2023)
 - 2.2.2 World Prostate Cancer PARP Inhibitor Drugs Consumption Forecast by Region (2024-2029)
- 2.3 United States Prostate Cancer PARP Inhibitor Drugs Consumption (2018-2029)
- 2.4 China Prostate Cancer PARP Inhibitor Drugs Consumption (2018-2029)

- 2.5 Europe Prostate Cancer PARP Inhibitor Drugs Consumption (2018-2029)
- 2.6 Japan Prostate Cancer PARP Inhibitor Drugs Consumption (2018-2029)
- 2.7 South Korea Prostate Cancer PARP Inhibitor Drugs Consumption (2018-2029)
- 2.8 ASEAN Prostate Cancer PARP Inhibitor Drugs Consumption (2018-2029)
- 2.9 India Prostate Cancer PARP Inhibitor Drugs Consumption (2018-2029)

3 WORLD PROSTATE CANCER PARP INHIBITOR DRUGS MANUFACTURERS COMPETITIVE ANALYSIS

- 3.1 World Prostate Cancer PARP Inhibitor Drugs Production Value by Manufacturer (2018-2023)
- 3.2 World Prostate Cancer PARP Inhibitor Drugs Production by Manufacturer (2018-2023)
- 3.3 World Prostate Cancer PARP Inhibitor Drugs Average Price by Manufacturer (2018-2023)
- 3.4 Prostate Cancer PARP Inhibitor Drugs Company Evaluation Quadrant
- 3.5 Industry Rank and Concentration Rate (CR)
 - 3.5.1 Global Prostate Cancer PARP Inhibitor Drugs Industry Rank of Major Manufacturers
 - 3.5.2 Global Concentration Ratios (CR4) for Prostate Cancer PARP Inhibitor Drugs in 2022
 - 3.5.3 Global Concentration Ratios (CR8) for Prostate Cancer PARP Inhibitor Drugs in 2022
- 3.6 Prostate Cancer PARP Inhibitor Drugs Market: Overall Company Footprint Analysis
 - 3.6.1 Prostate Cancer PARP Inhibitor Drugs Market: Region Footprint
 - 3.6.2 Prostate Cancer PARP Inhibitor Drugs Market: Company Product Type Footprint
 - 3.6.3 Prostate Cancer PARP Inhibitor Drugs Market: Company Product Application Footprint
- 3.7 Competitive Environment
 - 3.7.1 Historical Structure of the Industry
 - 3.7.2 Barriers of Market Entry
 - 3.7.3 Factors of Competition
- 3.8 New Entrant and Capacity Expansion Plans
- 3.9 Mergers, Acquisition, Agreements, and Collaborations

4 UNITED STATES VS CHINA VS REST OF THE WORLD

- 4.1 United States VS China: Prostate Cancer PARP Inhibitor Drugs Production Value Comparison

4.1.1 United States VS China: Prostate Cancer PARP Inhibitor Drugs Production Value Comparison (2018 & 2022 & 2029)

4.1.2 United States VS China: Prostate Cancer PARP Inhibitor Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)

4.2 United States VS China: Prostate Cancer PARP Inhibitor Drugs Production Comparison

4.2.1 United States VS China: Prostate Cancer PARP Inhibitor Drugs Production Comparison (2018 & 2022 & 2029)

4.2.2 United States VS China: Prostate Cancer PARP Inhibitor Drugs Production Market Share Comparison (2018 & 2022 & 2029)

4.3 United States VS China: Prostate Cancer PARP Inhibitor Drugs Consumption Comparison

4.3.1 United States VS China: Prostate Cancer PARP Inhibitor Drugs Consumption Comparison (2018 & 2022 & 2029)

4.3.2 United States VS China: Prostate Cancer PARP Inhibitor Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)

4.4 United States Based Prostate Cancer PARP Inhibitor Drugs Manufacturers and Market Share, 2018-2023

4.4.1 United States Based Prostate Cancer PARP Inhibitor Drugs Manufacturers, Headquarters and Production Site (States, Country)

4.4.2 United States Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production Value (2018-2023)

4.4.3 United States Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production (2018-2023)

4.5 China Based Prostate Cancer PARP Inhibitor Drugs Manufacturers and Market Share

4.5.1 China Based Prostate Cancer PARP Inhibitor Drugs Manufacturers, Headquarters and Production Site (Province, Country)

4.5.2 China Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production Value (2018-2023)

4.5.3 China Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production (2018-2023)

4.6 Rest of World Based Prostate Cancer PARP Inhibitor Drugs Manufacturers and Market Share, 2018-2023

4.6.1 Rest of World Based Prostate Cancer PARP Inhibitor Drugs Manufacturers, Headquarters and Production Site (State, Country)

4.6.2 Rest of World Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production Value (2018-2023)

4.6.3 Rest of World Based Manufacturers Prostate Cancer PARP Inhibitor Drugs

Production (2018-2023)

5 MARKET ANALYSIS BY TYPE

5.1 World Prostate Cancer PARP Inhibitor Drugs Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 Lynparza

5.2.2 Zejula

5.2.3 Talzenna

5.2.4 Fluzoparib

5.2.5 PamiPali

5.2.6 Other

5.3 Market Segment by Type

5.3.1 World Prostate Cancer PARP Inhibitor Drugs Production by Type (2018-2029)

5.3.2 World Prostate Cancer PARP Inhibitor Drugs Production Value by Type (2018-2029)

5.3.3 World Prostate Cancer PARP Inhibitor Drugs Average Price by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

6.1 World Prostate Cancer PARP Inhibitor Drugs Market Size Overview by Application: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 Hospital

6.2.2 Specialty Clinic

6.2.3 other

6.3 Market Segment by Application

6.3.1 World Prostate Cancer PARP Inhibitor Drugs Production by Application (2018-2029)

6.3.2 World Prostate Cancer PARP Inhibitor Drugs Production Value by Application (2018-2029)

6.3.3 World Prostate Cancer PARP Inhibitor Drugs Average Price by Application (2018-2029)

7 COMPANY PROFILES

7.1 AstraZeneca

- 7.1.1 AstraZeneca Details
- 7.1.2 AstraZeneca Major Business
- 7.1.3 AstraZeneca Prostate Cancer PARP Inhibitor Drugs Product and Services
- 7.1.4 AstraZeneca Prostate Cancer PARP Inhibitor Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
- 7.1.5 AstraZeneca Recent Developments/Updates
- 7.1.6 AstraZeneca Competitive Strengths & Weaknesses
- 7.2 Merck & Co., Inc
 - 7.2.1 Merck & Co., Inc Details
 - 7.2.2 Merck & Co., Inc Major Business
 - 7.2.3 Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Product and Services
 - 7.2.4 Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
 - 7.2.5 Merck & Co., Inc Recent Developments/Updates
 - 7.2.6 Merck & Co., Inc Competitive Strengths & Weaknesses
- 7.3 GSK
 - 7.3.1 GSK Details
 - 7.3.2 GSK Major Business
 - 7.3.3 GSK Prostate Cancer PARP Inhibitor Drugs Product and Services
 - 7.3.4 GSK Prostate Cancer PARP Inhibitor Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
 - 7.3.5 GSK Recent Developments/Updates
 - 7.3.6 GSK Competitive Strengths & Weaknesses
- 7.4 Pfizer
 - 7.4.1 Pfizer Details
 - 7.4.2 Pfizer Major Business
 - 7.4.3 Pfizer Prostate Cancer PARP Inhibitor Drugs Product and Services
 - 7.4.4 Pfizer Prostate Cancer PARP Inhibitor Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
 - 7.4.5 Pfizer Recent Developments/Updates
 - 7.4.6 Pfizer Competitive Strengths & Weaknesses
- 7.5 Johnson & Johnson
 - 7.5.1 Johnson & Johnson Details
 - 7.5.2 Johnson & Johnson Major Business
 - 7.5.3 Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Product and Services
 - 7.5.4 Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
 - 7.5.5 Johnson & Johnson Recent Developments/Updates
 - 7.5.6 Johnson & Johnson Competitive Strengths & Weaknesses

7.6 Takeda Pharmaceutical Company Limited

7.6.1 Takeda Pharmaceutical Company Limited Details

7.6.2 Takeda Pharmaceutical Company Limited Major Business

7.6.3 Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Product and Services

7.6.4 Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)

7.6.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates

7.6.6 Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses

7.7 BeiGene, Inc

7.7.1 BeiGene, Inc Details

7.7.2 BeiGene, Inc Major Business

7.7.3 BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Product and Services

7.7.4 BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)

7.7.5 BeiGene, Inc Recent Developments/Updates

7.7.6 BeiGene, Inc Competitive Strengths & Weaknesses

7.8 Jiangsu Hengrui Pharmaceuticals Co., Ltd

7.8.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd Details

7.8.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd Major Business

7.8.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Product and Services

7.8.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)

7.8.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd Recent Developments/Updates

7.8.6 Jiangsu Hengrui Pharmaceuticals Co., Ltd Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

8.1 Prostate Cancer PARP Inhibitor Drugs Industry Chain

8.2 Prostate Cancer PARP Inhibitor Drugs Upstream Analysis

8.2.1 Prostate Cancer PARP Inhibitor Drugs Core Raw Materials

8.2.2 Main Manufacturers of Prostate Cancer PARP Inhibitor Drugs Core Raw Materials

8.3 Midstream Analysis

8.4 Downstream Analysis

8.5 Prostate Cancer PARP Inhibitor Drugs Production Mode

8.6 Prostate Cancer PARP Inhibitor Drugs Procurement Model

8.7 Prostate Cancer PARP Inhibitor Drugs Industry Sales Model and Sales Channels

8.7.1 Prostate Cancer PARP Inhibitor Drugs Sales Model

8.7.2 Prostate Cancer PARP Inhibitor Drugs Typical Customers

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology

10.2 Research Process and Data Source

10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Prostate Cancer PARP Inhibitor Drugs Production Value by Region (2018, 2022 and 2029) & (USD Million)

Table 2. World Prostate Cancer PARP Inhibitor Drugs Production Value by Region (2018-2023) & (USD Million)

Table 3. World Prostate Cancer PARP Inhibitor Drugs Production Value by Region (2024-2029) & (USD Million)

Table 4. World Prostate Cancer PARP Inhibitor Drugs Production Value Market Share by Region (2018-2023)

Table 5. World Prostate Cancer PARP Inhibitor Drugs Production Value Market Share by Region (2024-2029)

Table 6. World Prostate Cancer PARP Inhibitor Drugs Production by Region (2018-2023) & (K Units)

Table 7. World Prostate Cancer PARP Inhibitor Drugs Production by Region (2024-2029) & (K Units)

Table 8. World Prostate Cancer PARP Inhibitor Drugs Production Market Share by Region (2018-2023)

Table 9. World Prostate Cancer PARP Inhibitor Drugs Production Market Share by Region (2024-2029)

Table 10. World Prostate Cancer PARP Inhibitor Drugs Average Price by Region (2018-2023) & (US\$/Unit)

Table 11. World Prostate Cancer PARP Inhibitor Drugs Average Price by Region (2024-2029) & (US\$/Unit)

Table 12. Prostate Cancer PARP Inhibitor Drugs Major Market Trends

Table 13. World Prostate Cancer PARP Inhibitor Drugs Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)

Table 14. World Prostate Cancer PARP Inhibitor Drugs Consumption by Region (2018-2023) & (K Units)

Table 15. World Prostate Cancer PARP Inhibitor Drugs Consumption Forecast by Region (2024-2029) & (K Units)

Table 16. World Prostate Cancer PARP Inhibitor Drugs Production Value by Manufacturer (2018-2023) & (USD Million)

Table 17. Production Value Market Share of Key Prostate Cancer PARP Inhibitor Drugs Producers in 2022

Table 18. World Prostate Cancer PARP Inhibitor Drugs Production by Manufacturer (2018-2023) & (K Units)

Table 19. Production Market Share of Key Prostate Cancer PARP Inhibitor Drugs Producers in 2022

Table 20. World Prostate Cancer PARP Inhibitor Drugs Average Price by Manufacturer (2018-2023) & (US\$/Unit)

Table 21. Global Prostate Cancer PARP Inhibitor Drugs Company Evaluation Quadrant

Table 22. World Prostate Cancer PARP Inhibitor Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2022

Table 23. Head Office and Prostate Cancer PARP Inhibitor Drugs Production Site of Key Manufacturer

Table 24. Prostate Cancer PARP Inhibitor Drugs Market: Company Product Type Footprint

Table 25. Prostate Cancer PARP Inhibitor Drugs Market: Company Product Application Footprint

Table 26. Prostate Cancer PARP Inhibitor Drugs Competitive Factors

Table 27. Prostate Cancer PARP Inhibitor Drugs New Entrant and Capacity Expansion Plans

Table 28. Prostate Cancer PARP Inhibitor Drugs Mergers & Acquisitions Activity

Table 29. United States VS China Prostate Cancer PARP Inhibitor Drugs Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 30. United States VS China Prostate Cancer PARP Inhibitor Drugs Production Comparison, (2018 & 2022 & 2029) & (K Units)

Table 31. United States VS China Prostate Cancer PARP Inhibitor Drugs Consumption Comparison, (2018 & 2022 & 2029) & (K Units)

Table 32. United States Based Prostate Cancer PARP Inhibitor Drugs Manufacturers, Headquarters and Production Site (States, Country)

Table 33. United States Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production Value, (2018-2023) & (USD Million)

Table 34. United States Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production Value Market Share (2018-2023)

Table 35. United States Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production (2018-2023) & (K Units)

Table 36. United States Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production Market Share (2018-2023)

Table 37. China Based Prostate Cancer PARP Inhibitor Drugs Manufacturers, Headquarters and Production Site (Province, Country)

Table 38. China Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production Value, (2018-2023) & (USD Million)

Table 39. China Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production Value Market Share (2018-2023)

- Table 40. China Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production (2018-2023) & (K Units)
- Table 41. China Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production Market Share (2018-2023)
- Table 42. Rest of World Based Prostate Cancer PARP Inhibitor Drugs Manufacturers, Headquarters and Production Site (States, Country)
- Table 43. Rest of World Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production Value, (2018-2023) & (USD Million)
- Table 44. Rest of World Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production Value Market Share (2018-2023)
- Table 45. Rest of World Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production (2018-2023) & (K Units)
- Table 46. Rest of World Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production Market Share (2018-2023)
- Table 47. World Prostate Cancer PARP Inhibitor Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
- Table 48. World Prostate Cancer PARP Inhibitor Drugs Production by Type (2018-2023) & (K Units)
- Table 49. World Prostate Cancer PARP Inhibitor Drugs Production by Type (2024-2029) & (K Units)
- Table 50. World Prostate Cancer PARP Inhibitor Drugs Production Value by Type (2018-2023) & (USD Million)
- Table 51. World Prostate Cancer PARP Inhibitor Drugs Production Value by Type (2024-2029) & (USD Million)
- Table 52. World Prostate Cancer PARP Inhibitor Drugs Average Price by Type (2018-2023) & (US\$/Unit)
- Table 53. World Prostate Cancer PARP Inhibitor Drugs Average Price by Type (2024-2029) & (US\$/Unit)
- Table 54. World Prostate Cancer PARP Inhibitor Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
- Table 55. World Prostate Cancer PARP Inhibitor Drugs Production by Application (2018-2023) & (K Units)
- Table 56. World Prostate Cancer PARP Inhibitor Drugs Production by Application (2024-2029) & (K Units)
- Table 57. World Prostate Cancer PARP Inhibitor Drugs Production Value by Application (2018-2023) & (USD Million)
- Table 58. World Prostate Cancer PARP Inhibitor Drugs Production Value by Application (2024-2029) & (USD Million)
- Table 59. World Prostate Cancer PARP Inhibitor Drugs Average Price by Application

(2018-2023) & (US\$/Unit)

Table 60. World Prostate Cancer PARP Inhibitor Drugs Average Price by Application (2024-2029) & (US\$/Unit)

Table 61. AstraZeneca Basic Information, Manufacturing Base and Competitors

Table 62. AstraZeneca Major Business

Table 63. AstraZeneca Prostate Cancer PARP Inhibitor Drugs Product and Services

Table 64. AstraZeneca Prostate Cancer PARP Inhibitor Drugs Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 65. AstraZeneca Recent Developments/Updates

Table 66. AstraZeneca Competitive Strengths & Weaknesses

Table 67. Merck & Co., Inc Basic Information, Manufacturing Base and Competitors

Table 68. Merck & Co., Inc Major Business

Table 69. Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Product and Services

Table 70. Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 71. Merck & Co., Inc Recent Developments/Updates

Table 72. Merck & Co., Inc Competitive Strengths & Weaknesses

Table 73. GSK Basic Information, Manufacturing Base and Competitors

Table 74. GSK Major Business

Table 75. GSK Prostate Cancer PARP Inhibitor Drugs Product and Services

Table 76. GSK Prostate Cancer PARP Inhibitor Drugs Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 77. GSK Recent Developments/Updates

Table 78. GSK Competitive Strengths & Weaknesses

Table 79. Pfizer Basic Information, Manufacturing Base and Competitors

Table 80. Pfizer Major Business

Table 81. Pfizer Prostate Cancer PARP Inhibitor Drugs Product and Services

Table 82. Pfizer Prostate Cancer PARP Inhibitor Drugs Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 83. Pfizer Recent Developments/Updates

Table 84. Pfizer Competitive Strengths & Weaknesses

Table 85. Johnson & Johnson Basic Information, Manufacturing Base and Competitors

Table 86. Johnson & Johnson Major Business

Table 87. Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Product and Services

Table 88. Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 89. Johnson & Johnson Recent Developments/Updates

Table 90. Johnson & Johnson Competitive Strengths & Weaknesses

Table 91. Takeda Pharmaceutical Company Limited Basic Information, Manufacturing Base and Competitors

Table 92. Takeda Pharmaceutical Company Limited Major Business

Table 93. Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Product and Services

Table 94. Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 95. Takeda Pharmaceutical Company Limited Recent Developments/Updates

Table 96. Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses

Table 97. BeiGene, Inc Basic Information, Manufacturing Base and Competitors

Table 98. BeiGene, Inc Major Business

Table 99. BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Product and Services

Table 100. BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 101. BeiGene, Inc Recent Developments/Updates

Table 102. Jiangsu Hengrui Pharmaceuticals Co., Ltd Basic Information, Manufacturing Base and Competitors

Table 103. Jiangsu Hengrui Pharmaceuticals Co., Ltd Major Business

Table 104. Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Product and Services

Table 105. Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 106. Global Key Players of Prostate Cancer PARP Inhibitor Drugs Upstream (Raw Materials)

Table 107. Prostate Cancer PARP Inhibitor Drugs Typical Customers

Table 108. Prostate Cancer PARP Inhibitor Drugs Typical Distributors

List Of Figures

LIST OF FIGURES

Figure 1. Prostate Cancer PARP Inhibitor Drugs Picture

Figure 2. World Prostate Cancer PARP Inhibitor Drugs Production Value: 2018 & 2022 & 2029, (USD Million)

Figure 3. World Prostate Cancer PARP Inhibitor Drugs Production Value and Forecast (2018-2029) & (USD Million)

Figure 4. World Prostate Cancer PARP Inhibitor Drugs Production (2018-2029) & (K Units)

Figure 5. World Prostate Cancer PARP Inhibitor Drugs Average Price (2018-2029) & (US\$/Unit)

Figure 6. World Prostate Cancer PARP Inhibitor Drugs Production Value Market Share by Region (2018-2029)

Figure 7. World Prostate Cancer PARP Inhibitor Drugs Production Market Share by Region (2018-2029)

Figure 8. North America Prostate Cancer PARP Inhibitor Drugs Production (2018-2029) & (K Units)

Figure 9. Europe Prostate Cancer PARP Inhibitor Drugs Production (2018-2029) & (K Units)

Figure 10. China Prostate Cancer PARP Inhibitor Drugs Production (2018-2029) & (K Units)

Figure 11. Japan Prostate Cancer PARP Inhibitor Drugs Production (2018-2029) & (K Units)

Figure 12. Prostate Cancer PARP Inhibitor Drugs Market Drivers

Figure 13. Factors Affecting Demand

Figure 14. World Prostate Cancer PARP Inhibitor Drugs Consumption (2018-2029) & (K Units)

Figure 15. World Prostate Cancer PARP Inhibitor Drugs Consumption Market Share by Region (2018-2029)

Figure 16. United States Prostate Cancer PARP Inhibitor Drugs Consumption (2018-2029) & (K Units)

Figure 17. China Prostate Cancer PARP Inhibitor Drugs Consumption (2018-2029) & (K Units)

Figure 18. Europe Prostate Cancer PARP Inhibitor Drugs Consumption (2018-2029) & (K Units)

Figure 19. Japan Prostate Cancer PARP Inhibitor Drugs Consumption (2018-2029) & (K Units)

- Figure 20. South Korea Prostate Cancer PARP Inhibitor Drugs Consumption (2018-2029) & (K Units)
- Figure 21. ASEAN Prostate Cancer PARP Inhibitor Drugs Consumption (2018-2029) & (K Units)
- Figure 22. India Prostate Cancer PARP Inhibitor Drugs Consumption (2018-2029) & (K Units)
- Figure 23. Producer Shipments of Prostate Cancer PARP Inhibitor Drugs by Manufacturer Revenue (\$MM) and Market Share (%): 2022
- Figure 24. Global Four-firm Concentration Ratios (CR4) for Prostate Cancer PARP Inhibitor Drugs Markets in 2022
- Figure 25. Global Four-firm Concentration Ratios (CR8) for Prostate Cancer PARP Inhibitor Drugs Markets in 2022
- Figure 26. United States VS China: Prostate Cancer PARP Inhibitor Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
- Figure 27. United States VS China: Prostate Cancer PARP Inhibitor Drugs Production Market Share Comparison (2018 & 2022 & 2029)
- Figure 28. United States VS China: Prostate Cancer PARP Inhibitor Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
- Figure 29. United States Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production Market Share 2022
- Figure 30. China Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production Market Share 2022
- Figure 31. Rest of World Based Manufacturers Prostate Cancer PARP Inhibitor Drugs Production Market Share 2022
- Figure 32. World Prostate Cancer PARP Inhibitor Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
- Figure 33. World Prostate Cancer PARP Inhibitor Drugs Production Value Market Share by Type in 2022
- Figure 34. Lynparza
- Figure 35. Zejula
- Figure 36. Talzenna
- Figure 37. Fluzoparib
- Figure 38. PamiPali
- Figure 39. Other
- Figure 40. World Prostate Cancer PARP Inhibitor Drugs Production Market Share by Type (2018-2029)
- Figure 41. World Prostate Cancer PARP Inhibitor Drugs Production Value Market Share by Type (2018-2029)
- Figure 42. World Prostate Cancer PARP Inhibitor Drugs Average Price by Type

(2018-2029) & (US\$/Unit)

Figure 43. World Prostate Cancer PARP Inhibitor Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029

Figure 44. World Prostate Cancer PARP Inhibitor Drugs Production Value Market Share by Application in 2022

Figure 45. Hospital

Figure 46. Specialty Clinic

Figure 47. other

Figure 48. World Prostate Cancer PARP Inhibitor Drugs Production Market Share by Application (2018-2029)

Figure 49. World Prostate Cancer PARP Inhibitor Drugs Production Value Market Share by Application (2018-2029)

Figure 50. World Prostate Cancer PARP Inhibitor Drugs Average Price by Application (2018-2029) & (US\$/Unit)

Figure 51. Prostate Cancer PARP Inhibitor Drugs Industry Chain

Figure 52. Prostate Cancer PARP Inhibitor Drugs Procurement Model

Figure 53. Prostate Cancer PARP Inhibitor Drugs Sales Model

Figure 54. Prostate Cancer PARP Inhibitor Drugs Sales Channels, Direct Sales, and Distribution

Figure 55. Methodology

Figure 56. Research Process and Data Source

I would like to order

Product name: Global Prostate Cancer PARP Inhibitor Drugs Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/G0FA94D324A7EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0FA94D324A7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

